Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes

• Autor(a) principal: Porta,Gilda
• Data de Publicação: 2019
• Outros Autores: Carvalho,Elisa de, Santos,Jorge L., Gama,Jorge, Borges,Cristian V., Seixas,Renata B.P.M., Ferreira,Alexandre R., Miura,Irene K., Silveira,Themis R., Silva,Luciana R., Fagundes,Eleonora D.T., Bellomo-Brandao,Maria A., Sawamura,Regina, Vieira,Sandra M., Melere,Melina U., Marques,Cibele D.F., Pugliese,Renata P., Danesi,Vera L., Porta,Adriana, Marsillac,Marise E., Valladares,Marcia A., Menezes,Daniela G., Kieling,Carlos, Paula,Mariana N. de, Vasconcelos,Juliana R., Ferreira,Cristina T., Perin,Nilza, Resende,Leonardo R., Maia,Jussara, Tommaso,Adriana M.A. De, Hessel,Gabriel
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Jornal de Pediatria (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572019000500419
• topic: Autoimmune hepatitis; Clinical; Laboratory; Treatments; Outcomes; Brazil

Abstract Objective: This large study with a long-term follow-up aimed to evaluate the clinical presentation, laboratory findings, histological profile, treatments, and outcomes of children and adolescents with autoimmune hepatitis. Methods: The medical records of 828 children and adolescents with autoimmune hepatitis were reviewed. A questionnaire was used to collect anonymous data on clinical presentation, biochemical and histological findings, and treatments. Results: Of all patients, 89.6% had autoimmune hepatitis-1 and 10.4% had autoimmune hepatitis-2. The female sex was predominant in both groups. The median age at symptom onset was 111.5 (6; 210) and 53.5 (8; 165) months in the patients with autoimmune hepatitis 1 and autoimmune hepatitis-2, respectively. Acute clinical onset was observed in 56.1% and 58.8% and insidious symptoms in 43.9% and 41.2% of the patients with autoimmune hepatitis-1 and autoimmune hepatitis-2, respectively. The risk of hepatic failure was 1.6-fold higher for autoimmune hepatitis-2. Fulminant hepatic failure occurred in 3.6% and 10.6% of the patients with autoimmune hepatitis-1 and autoimmune hepatitis-2, respectively; the risk was 3.1-fold higher for autoimmune hepatitis-2. The gamma globulin and immunoglobulin G levels were significantly higher in autoimmune hepatitis-1, while the immunoglobulin A and C3 levels were lower in autoimmune hepatitis-2. Cirrhosis was observed in 22.4% of the patients; biochemical remission was achieved in 76.2%. The actuarial survival rate was 93.0%. A total of 4.6% underwent liver transplantation, and 6.9% died (autoimmune hepatitis-1: 7.5%; autoimmune hepatitis-2: 2.4%). Conclusions: In this large clinical series of Brazilian children and adolescents, autoimmune hepatitis-1 was more frequent, and patients with autoimmune hepatitis-2 exhibited higher disease remission rates with earlier response to treatment. Patients with autoimmune hepatitis-1 had a higher risk of death.